Not yet recruiting NCT06876701
The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Bevacizumab.
- Who it may be relevant to
- Registry conditions: Acute Leukemia. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults
Interventions
- Drug Bevacizumab
Evaluation of the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults
Primary outcome measures
- Negative conversion rate of evaluable residual lesions (MRD) [Time frame: 1 year]
Eligibility criteria
Inclusion criteria
- Patients fully understand this study, voluntarily participate and sign an informed consent form (ICF);
- Age: 18-75 years old (including boundary values of 18 and 75);
- Clinically diagnosed adult Mixed Phenotype Acute Leukemia (WHO 2016 criteria) patients with CD19 positivity
Exclusion criteria
The subject's previous history of anti-tumor treatment meets one of the following conditions:
- Individuals who have previously received bevacizumab
- Individuals who have received CAR-T therapy or other gene modified cell therapies prior to screening;
- Within 5 half lives of the first use of the investigational drug, having received anti-tumor treatment including surgery, chemotherapy, targeted therapy, or participating in other clinical trials and receiving clinical trial medication;
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Shanghai Zhaxin integrated hospital of traditional Chinese and Western Medicine — Shanghai
Identifiers
NCT: NCT06876701 · CSPC-DED-AML-KXX